Zacks Investment Research on MSN

5 big drug stocks that may continue to outperform in 2026

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...
Cancer Therapy Advisor

Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
pharmaphorum

J&J's subcutaneous Rybrevant cleared by FDA

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Yahoo Finance

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when ...

HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and ...
Cure Today

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

Rybrevant Faspro, a subcutaneous therapy, offers a faster, less invasive treatment for EGFR-mutated NSCLC, reducing administration time and reactions compared to intravenous methods. The PALOMA-3 ...
WebMD

FDA Approves Rybrevant Faspro: An Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer

Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
Seeking Alpha

J&J wins FDA nod for Rybrevant injectable in lung cancer

Johnson & Johnson (JNJ) announced on Thursday that the U.S. FDA approved an injectable version of its cancer medicine Rybrevant, developed with Halozyme (HALO) as part of a combination regimen for ...
Morningstar

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration ...
Yahoo Finance

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...
Hosted on MSN

Johnson & Johnson announces FDA-approved Rybrevant in NSCLC patients

Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously administered therapy for patients with epidermal growth ...
FiercePharma

J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso

A year after an FDA rejection, Johnson & Johnson has won approval for a more convenient version of its lung cancer drug Rybrevant to better challenge AstraZeneca’s Tagrisso. Rybrevant Faspro, a ...